Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF), an early stage pharmaceutical company, announced today the appointment of Dr. Domenico Spina as a director of the company. Earning his PhD from the University of Western Australia in 1988, Dr. Spina is currently head of Pharmacology and Therapeutics Research within the Institute of Pharmaceutical Science, and a member of the British Pharmacological Society, American Thoracic Society and the European Respiratory Society.
Veritas Pharma is focused on using their knowledge to streamline the development of cannabis-based treatments to capture considerable market share. The company is developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, nausea, and epilepsy. Dr. Spina’s research interest includes inflammation of the airways with particular emphasis on understanding the pharmacology of drugs used to treat cough, asthma, chronic obstructive disease and lung injury with a view to developing novel therapies for these conditions.
“I have been involved in investigating the role of phytocannabinoids as potential cannabis based treatments for respiratory disease in collaboration with GW Pharma; and after reviewing the team Dr. Lui Franciosi has assembled with Cannevert Therapeutics Ltd., I am more excited to be invited to be part of such a strong, well known, diverse team,” said Spina.
Along with this major operational milestone, through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., Veritas Pharma has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. The company has also has begun trading on the Frankfurt Stock Exchange under the trading symbol “2VP.”
With the addition of Dr. Spina, Veritas Pharma continues to strengthen their leadership and inter-disciplinary teams, that includes chemists, pharmacologists, anesthetists, and clinical pharmacologists, and aid in the removal of social and professional stigmas surrounding the medical cannabis industry. “Having Dr. Spina on board, adds to the team,” said Lui Franciosi, CEO of Veritas Pharma. “His vast knowledge in the respiratory field will add another layer of expertise for Veritas moving into the future.”
For more information about Veritas Pharma, visit www.veritaspharmainc.com.
In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. has been compensated 137,500 common shares plus warrants by Veritas Pharma, Inc. for its profile in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer